Edgen Stock·Sep 09 2025, 22:42戻る
戻る
Sanofi Secures FDA Approval for Wayrilz, Bolstering Rare Disease Portfolio
Edgen Stock·Sep 09 2025, 22:42
[1] A Look at Sanofi (ENXTPA:SAN) Valuation Following FDA Approval of Breakthrough Rare Disease Therapy (https://finance.yahoo.com/news/look-sanofi-en ...)[2] Sanofi's Wayrilz: A Strategic Breakthrough in the BTK Inhibitor Market for Rare Blood Disorders - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] Sanofi's Wayrilz: A Game-Changer in Rare Disease and Immunology Markets - AInvest (https://ainvest.com/sanofis-wayrilz-a-game-ch ...)